Consortia for Structure-based Immunogen Design for HIV (CSID-HIV) (UM1 Clinical Trial Not Allowed)

The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance the National Institutes of Health (NIH) mission by supporting research to support structure-based immunogen design to advance the development and selection of HIV immunogens that induce broadly neutralizing antibody (bNAb) responses. These immunogens will then be advanced into clinical testing. Consortium research should address critical immunogen design roadblocks in discovering and developing safe and effective HIV bNAbs and bNAb responses that can be used as therapeutics, as well as guide vaccine development that could be used for both HIV treatment and prevention. This notice of funding opportunity (NOFO) will support coordinated multidisciplinary efforts on bNAb and vaccine discovery and applied research, emphasizing iterative approaches to expedite HIV therapeutics and vaccine development. The ultimate goal is to achieve proof of concept of therapeutic strategies using bNABs and vaccine-induction of bNAbs targeting multiple bNAb sites, while also integrating other cooperative immune responses. The technology being developed through these consortia will be applicable to other fields facing significant hurdles in viral antigen therapeutic targeting and vaccine design. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.